Latest Breaking News On - Gilles gallant - Page 1 : vimarsana.com

Data demonstrate higher internalization in cMET positive (cMET+) tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of non-small cell lung cancer (NSCLC), as compared to other cMET-targeting ADCsData establish preclinical proof of concept for MYTX-011.

South koreaUnited statesNimish geraCritical rev clin lab sciCompany fatecontrolAmerican association for cancer research annual meetingMythic therapeuticsAmerican associationCancer research annualGilles gallantChief development officerVice presidentTargeting protein kinasesPoster sectionBoard numberAbstract number